Business Context and Reporting Period
This Form 8-K is filed by BioZone Pharmaceuticals, Inc. (not Cocrystal Pharma, Inc. as indicated in the metadata) for the reporting period ending October 31, 2011. The company is incorporated in Nevada and is based in Englewood Cliffs, NJ. The filing reports on unregistered sales of equity securities.
Key Financial Metrics
The filing details a specific capital raise event rather than comprehensive financial statements.
- Equity Issuance: 455,000 shares of common stock.
- Price per Share: $1.00.
- Total Proceeds: $455,000.
- Investor Type: Accredited investor.
- Regulatory Basis: Section 4(2) of the Securities Act of 1933 and Rule 506.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity beyond the proceeds from this specific transaction.
Material Changes
The primary material change is the increase in outstanding common stock by 455,000 shares and the corresponding increase in cash assets from the private placement. No other material changes to operations or financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors related to the company's operations. The transaction was executed via subscription agreements dated October 31, 2011, and November 1, 2011, with shares issued on November 3, 2011.
Investor Verification Checklist
- Verify the correct registrant name is BioZone Pharmaceuticals, Inc., not Cocrystal Pharma, Inc.
- Confirm the total capital raised of $455,000 from the private placement.
- Review the attached Form of Subscription Agreement (Exhibit 10.1) for specific terms and conditions.
- Check subsequent filings for the impact of this capital raise on the company's cash position and dilution.